Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(9):619-621; doi:10.1093/jnci/dji126
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

EDITORIAL

Medroxyprogesterone Acetate and Metastases: Of Mice and (wo)Men

V. Craig Jordan

Correspondence to: V. Craig Jordan, OBE, PhD, DSc, Fox Chase Cancer Center, Medical Sciences, 333 E. Cottman Ave., Philadelphia, PA 19111 (e-mail: v.craig.jordan@fccc.edu).

The first 150 words of the full text of this article appear below.

The current research strategy for the treatment of cancer is to identify a specific target and develop drugs to block tumor growth or destroy cancer cells. This approach must also produce minimal side effects for the patient. Regrettably, it is unlikely that there is a single answer to cancer, but it is hoped that a combination of incremental advances that retard cancer development and progression will, together, create improvements in cancer care.

In the case of breast cancer, there has been a two-pronged attack on the disease, and both approaches, which target the estrogen receptor (ER), have had some measure of success in the clinic (1). Chemoprevention of breast cancer with the antiestrogen tamoxifen can reduce the incidence of tumors by approximately 50% in high-risk women (2). Similarly, preventing the growth of metastases by the appropriate application of adjuvant endocrine therapy following surgery can . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
A. F. Chambers
Re: Medroxyprogesterone Acetate and Metastases: Of Mice and (Wo)Men
J Natl Cancer Inst, August 17, 2005; 97(16): 1225 - 1225.
[Full Text] [PDF]